Astellas exits Amgen JV

23 January 2020

Japanese drugmaker Astellas Pharma (TYO: 4503) has sold the stake in its joint venture (JV) with US biotech major Amgen (Nasdaq: AMGN).

Amgen will buy the remaining 49% stake in the JV, effectively ending the strategic alliance contract signed between the two companies in 2013.

The JV, previously named Amgen Astellas BioPharma, will change its name to Amgen KK, and will relocate its headquarters to a new location in Tokyo. Steve Sugino will remain president and representative director of the unit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK